Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Eligibility Criteria

Patients are only eligible after signing the informed consent form and must meet all of the following criteria to be eligible for the Medical Access Program. Inclusion Criteria: * The patient has at least one SCLC lesion that has not been previously irradiated. * The patient is aged ≥18 years or older. * The patient has histologically or cytologically documented ES-SCLC. * The patient had prior therapy with platinum-based chemotherapy and one additional treatment as systemic therapy for extensive-stage disease. * The patient has received prior treatment with a minimum of two previous lines of systemic therapy. * The patient has a documented radiological disease progression on or after the most recent systemic therapy. * The patient has an ECOG PS of 0-1. * The patient has a life expectancy of ≥3 months * The patient has adequate organ and bone marrow function as defined in the protocol within 7 days prior to Cycle 1 Day 1 of I-DXd treatment. Transfusion (red blood cell or platelet) o…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source